OCI Expands Pharmaceutical and Bio Business... Becomes Largest Shareholder of Bukwang Pharm
Signed Stock Trading Contract Worth 146.1 Billion Won
[Asia Economy Reporter Oh Hyung-gil] OCI has become the largest shareholder of Bukwang Pharm and is accelerating its business in the pharmaceutical and bio sectors.
On the 22nd, OCI announced that it signed a stock purchase agreement to acquire approximately 7.73 million shares held by special related parties, the largest shareholders of Bukwang Pharm, by investing 146.1 billion KRW. With this investment, OCI will hold about an 11% stake in Bukwang Pharm and secure the position of the largest shareholder.
Through a shareholders' agreement, a foundation for joint management was established to mutually consult on important management decisions such as new product development, investment decisions, and large-scale borrowing.
The two companies have accumulated experience in joint management and investment cooperation through the joint venture 'BNO Bio,' which they jointly established in 2018. OCI is reported to have confirmed high future growth value based on Bukwang Pharm's capabilities and potential in new drug development.
Bukwang Pharm, established in 1960, is a pharmaceutical company that has expanded its main drug development pipeline focusing on treatments for brain diseases and anticancer drugs. It currently has various global partnerships with more than 30 overseas companies.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Trump Puts Attack on Hold, but "Only for a Certain Period"... Treasury Announces Sweeping Sanctions
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Lee Woo-hyun, Vice Chairman of OCI, stated, "It is meaningful to establish a growth foundation in the pharmaceutical, bio, and research and development fields through the investment in Bukwang Pharm's shares," adding, "We will discover various synergy areas and grow Bukwang Pharm into a world-class pharmaceutical and bio company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
